

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISIÓN DE NUEVAS CREACIONES

E.

S.

D.

Re: Expediente No. NC2016/0002889
Solicitud de patente Título "PIRIDILAMIDINAS FUNGICIDAS NOVEDOSAS"
Solicitante: SYNGENTA PARTICIPATIONS AG
Nuestra Ref.: P2016/000041

MEMORIAL DE AGILIZACIÓN

J. IAN RAISBECK, mayor de edad y vecino de Bogotá, D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad solicitante, como consta en el poder otorgado por el solicitante, me permito solicitar la agilización del trámite correspondiente a la solicitud de patente de la referencia.

Adicionalmente, me permito informar a ese Despacho que la Oficina Europea de Patentes concedió la patente a la solicitud EP 14164464, sobre la cual se reclama prioridad dentro de la solicitud fase nacional PCT de la referencia. Para su información adjunto copia de la Decisión de otorgar una patente europea emitida por la Oficina Europea de Patentes el 2 de noviembre de 2018, así como copia de la Comunicación de la Intención para Conceder una Patente de fecha 17 de agosto de 2018. Como se indica en este último documento, la EPO informa la concesión de las Reivindicaciones 1 a 13 presentadas ante esa Oficina el 7 de junio de 2017. Adjunto también copia de las Reivindicaciones mencionadas.

Como podrá verificar ese Despacho, las Reivindicaciones 1 a 10 concedidas dentro de la patente europea corresponden en su totalidad a las Reivindicaciones 1 a 10 actualmente en trámite bajo el expediente de la referencia. Cabe resaltar que dentro del trámite de la solicitud europea, como de la solicitud PCT, la Oficina Europea de Patentes tuvo en consideración los documentos D1 (WO2012146125) y D2 (WO2008101682), que fueron citados por ese Despacho dentro del trámite de la presente solicitud de patente como fundamento de las objeciones por falta de novedad.

Reconociendo de antemano la autonomía de ese Despacho para el estudio de las solicitudes de patente en Colombia, respetuosamente solicito se tenga en consideración la decisión de la Oficina Europea de Patentes, como un referente sobre la patentabilidad de la materia reclamada en la presente invención en vista del mismo arte previo

Atentamente,



J. IAN RAISBECK
C.C. 79'376.996 de Bogotá D.C.
T.P. 135.799 del C. S. de la J.

Anexos:

- Decisión de otorgar una patente europea emitida por la Oficina Europea de Patentes el 2 de noviembre de 2018.
- Comunicación de la Intención para Conceder una Patente de fecha 17 de agosto de 2018.
- Copia de las Reivindicaciones 1 a 13 presentadas ante la EPO el 7 de junio de 2017 objeto de la patente concedida.

Questions about this communication ?

Contact Customer Services at www.epo.org/contact



Syngenta International AG
CHBS-B4.8
Schwarzwaldallee 215
4058 Basel
SUISSE

Date

02.11.18

Reference 80351-EP-ORG-X1	Application No./Patent No. 15715205.9 - 1110 / 3129355
Applicant/Proprietor Syngenta Participations AG	

Decision to grant a European patent pursuant to Article 97(1) EPC

Following examination of European patent application No. 15715205.9 a European patent with the title and the supporting documents indicated in the communication pursuant to Rule 71(3) EPC (EPO Form 2004C) or in the information (EPO Form 2004W, cf. Notice from the EPO dated 8 June 2015, OJ EPO 2015, A52) dated 17.08.18 is hereby granted in respect of the designated Contracting States.

Patent No. : 3129355
Date of filing : 31.03.15
Priority claimed : 11.04.14/EPA 14164464

Designated Contracting States
and Proprietor(s) : AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI
LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Syngenta Participations AG
Schwarzwaldallee 215
4058 Basel/CH

This decision will take effect on the date on which the European Patent Bulletin mentions the grant (Art. 97(3) EPC).

The mention of the grant will be published in European Patent Bulletin 18/48 of 28.11.18.

Examining Division

Cortés Suárez, José

Gettins, Marc

Beligny, Samuel



ANMERKUNG ZUR ENTSCHEIDUNG ÜBER DIE ERTEILUNG
EINES EUROPÄISCHEN PATENTS (EPA Form 2006)

1. **EPA Informationsbroschüre "Nationales Recht zum EPÜ"**

Diese Broschüre enthält nützliche Informationen zu den formalen Erfordernissen und den Handlungen, die vor den Patentbehörden der Vertragsstaaten vorzunehmen sind, um Rechte in diesen Staaten zu erlangen. Da diese Handlungen einem ständigen Wandel unterworfen sind, sollte immer nur die neueste Ausgabe der Broschüre benutzt werden. Nachträgliche Informationen werden im Amtsblatt veröffentlicht.

2. **Übersetzung der europäischen Patentschrift nach Artikel 65 (1) des Europäischen Patentübereinkommens**

Sie werden erneut darauf hingewiesen, dass bestimmte Vertragsstaaten nach Artikel 65 (1) EPÜ eine Übersetzung der europäischen Patentschrift verlangen; hierauf wird in der Mitteilung gemäß Regel 71 (5) EPÜ verwiesen. Die Nichteinreichung dieser Übersetzung kann zur Folge haben, dass das Patent in dem betreffenden Staat/in den betreffenden Staaten als von Anfang an nicht eingetreten gilt. Weitere Einzelheiten entnehmen Sie bitte der oben genannten Broschüre.

3. **Zahlung von Jahresgebühren für europäische Patente**

Nach Artikel 141 EPU können "nationale" Jahresgebühren für das europäische Patent für die Jahre erhoben werden, die an das Jahr anschließen, in dem der Hinweis auf die Erteilung des europäischen Patents im "Europäischen Patentblatt" bekanntgemacht wird. Weitere Einzelheiten entnehmen Sie bitte der oben genannten Broschüre.

NOTE RELATING TO THE DECISION TO GRANT A
EUROPEAN PATENT (EPO Form 2006)

1. **EPO Information Brochure "National law relating to the EPC"**

This brochure provides useful information regarding formal requirements and the steps to be taken before the patent authorities of the Contracting States in order to acquire rights in those states. Since the necessary steps are subject to change the latest edition of the brochure should always be used. Subsequent information is published in the Official Journal.

2. **Translation of the European patent application under Article 65(1) of the European Patent Convention**

Your attention is again drawn to the requirements regarding translation of the European patent specification laid down by a number of Contracting States under Article 65(1) EPC, to which reference is made in the communication under Rule 71(5) EPC. Failure to supply such translation(s) may result in the patent being deemed to be void "ab initio" in the State(s) in question. For further details you are recommended to consult the above-mentioned brochure.

3. **Payment of renewal fees for European patents**

Under Article 141 EPC "national" renewal fees in respect of a European patent may be imposed for the years which follow that in which the mention of the grant of the European patent is published in the "European Patent Bulletin". For further details you are recommended to consult the above-mentioned brochure.

REMARQUE RELATIVE A LA DECISION DE DELIVRANCE
D'UN BREVET EUROPEEN (OEB Form 2006)

1. **Brochure d'information de l'OEB "Droit national relatif à la CBE"**

Cette brochure fournit d'utiles renseignements sur les conditions de forme requises et sur les actes à accomplir auprès des offices de brevet des Etats contractants aux fins d'obtenir des droits dans les Etats contractants. Etant donné que les actes indispensables sont susceptibles de modifications, il serait bon de toujours consulter la dernière édition de la brochure. Toute information ultérieure est publiée au Journal Officiel.

2. **Traduction du fascicule du brevet européen en vertu de l'article 65(1) de la Convention sur le brevet européen**

Votre attention est de nouveau attirée sur l'obligation faite par certains Etats contractants, en vertu de l'article 65(1) CBE, de fournir une traduction du fascicule du brevet européen, à laquelle il est fait référence dans la notification établie conformément à la règle 71(5) CBE. Si la(les) traduction(s) n'est(ne sont) pas fournie(s), le brevet européen peut, dès l'origine, être réputé sans effet dans cet(ces) Etat(s). Pour plus de détails, nous vous renvoyons à la brochure susmentionnée.

3. **Paiement des taxes annuelles pour le brevet européen**

Conformément à l'article 141 CBE des taxes annuelles "nationales" dues au titre du brevet européen peuvent être perçues pour les années suivant celle au cours de laquelle la mention de la délivrance du brevet européen est publiée au "Bulletin européen des brevets". Pour plus de détails, nous vous renvoyons à la brochure susmentionnée.



Syngenta International AG
CHBS-B4.8
Schwarzwaldallee 215
4058 Basel
SUISSE

Formalities Officer
Name: Pfau, Andrea
Tel: +49 89 2399 - 6731
or call
+31 (0)70 340 45 00

Application No. 15 715 205.9 - 1110	Ref. 80351-EP-ORG-X1	Date 17.08.2018
Applicant Syngenta Participations AG		

Communication under Rule 71(3) EPC

1. Intention to grant

You are informed that the examining division intends to grant a European patent on the basis of the above application, with the text and drawings and the related bibliographic data as indicated below.

A copy of the relevant documents is enclosed.

1.1 In the text for the Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT
RO RS SE SI SK SM TR

Description, Pages

1-39 filed in electronic form on 28-05-2018

Claims, Numbers

1-13 filed in electronic form on 07-06-2017

1.2 Bibliographic data

The title of the invention in the three official languages of the European Patent Office, the international patent classification, the designated contracting states, the registered name(s) of the applicant(s) and the other bibliographic data are shown on **EPO Form 2056** (enclosed).

2. Invitation

You are invited, **within a non-extendable period of four months** of notification of this communication,

2.1 to EITHER approve the text communicated above and verify the bibliographic data (Rule 71(5) EPC)

- (1) by filing a translation of the claim(s) in the other two official languages of the EPO

Fee code	EUR
----------	-----

- (2a) by paying the fee for grant including the fee for publication:
minus any amount already paid (Rule 71a(5) EPC):

007	925.00
	0.00

Total amount:	925.00
---------------	--------

- (3) by paying additional claims fees under Rule 71(4) EPC;
number of claims fees payable: 0
minus any amount already paid (Rule 71a(5) EPC):

016	0.00
	0.00

Total amount:	0.00
---------------	------

Important: If the translations of the claims and fees have already been filed and paid respectively in reply to a previous communication under Rule 71(3) EPC, e.g. in the case of resumption of examination after approval (see Guidelines C-V, 6), **agreement as to the text to be granted** (Rule 71a(1) EPC) must be expressed within the same time limit (e.g. by approving the text and verifying the bibliographic data, by confirming that grant proceedings can go ahead with the documents on file and/or by stating which translations of the claims already on file are to be used).

Note 1: See "Notes concerning fee payments" below.

Note 2: Any overpaid "minus" amounts will be refunded when the decision to grant (EPO Form 2006A) has been issued.

Note 3: For the calculation of the grant fee under Article 2(2), No. 7, RFees (old fee structure), the number of pages is determined on the basis of a clean copy of the application documents, in which text deleted as a result of any amendments by the examining division is not shown. Such clean copy is made available via on-line file inspection only.

2.2 OR, in the case of disapproval, to request reasoned amendments or corrections to the text communicated above or keep to the latest text submitted by you (Rule 71(6) EPC).

In this case the translations of the claims and fee payments mentioned under point 2.1 above are NOT due.

The terms "amendment(s)" and "correction(s)" refer only to amendments or corrections of the application documents and not of other documents (e.g. bibliographic data, the designation of the inventor, etc.).

If filing amendments, you must identify them and indicate the basis for them in the application as filed. Failure to meet either requirement may lead to a communication from the examining division requesting that you correct this deficiency (Rule 137(4) EPC).

2.3 Bibliographic data

Where you request a change or correction of bibliographic data in response to the Rule 71(3) communication, this will **not** cause the sending of a further communication under Rule 71(3) EPC. You will still have to pay the fees and file translations in reply to the Rule 71(3) communication in the case of 2.1 above, unless you also file a reasoned request for amendments or corrections in response to the Rule 71(3) communication (see case 2.2 above).

3. Loss of rights

If neither of the two possible actions above (see points 2.1 or 2.2) is performed in due time, the European patent application will be deemed to be withdrawn (Rule 71(7) EPC).

4. Further procedure

4.1 In the case of point 2.1 above

- 4.1.1** The decision to grant the European patent will be issued, and the **mention of the grant** of the patent will be published in the European Patent Bulletin, if the requirements concerning the translation of the claims and the payment of all fees are fulfilled and there is agreement as to the text to be granted (Rule 71a(1) EPC).

Note on payment of the renewal fee:

If a renewal fee becomes due before the next possible date for publication of the mention of the grant of the European patent, publication will be effected only after the renewal fee and any additional fee have been paid (Rule 71a(4) EPC).

Under Article 86(2) EPC, the obligation to pay renewal fees to the European Patent Office terminates with the payment of the renewal fee due in respect of the year in which the mention of the grant of the European patent is published.

Note on payment of the designation fee(s):

If the designation fee(s) become(s) due after the communication under Rule 71(3) EPC, the mention of the grant of the European patent will not be published until these fees have been paid (Rule 71a(3) EPC).

- 4.1.2** After publication, the **European patent specification** can be downloaded free of charge from the EPO publication server <https://data.epo.org/publication-server>.

4.1.3 Filing of translations in the contracting states

As regards translation requirements prescribed by the contracting states under Article 65(1) EPC, please consult the website of the European Patent Office

www.epo.org → Law & practice → Legal texts, National law relating to the EPC

www.epo.org → Law & practice → All Legal texts → London Agreement

In the case of a valid extension or validation

As regards translation requirements prescribed by the extension or validation states, please consult the website of the European Patent Office

www.epo.org → Law & practice → Legal texts, National law relating to the EPC

Failure to supply a prescribed translation in a contracting state, or in an extension or validation state may result in the patent being deemed to be void *ab initio* in the state concerned (Art. 65(3) EPC).

4.2 In the case of 2.2 above

If the present communication under Rule 71(3) EPC is based on an auxiliary request and, within the time limit, you maintain the main request or a higher ranking request which is not allowable, the application will be refused (Art. 97(2) EPC).

If the examining division gives its consent to the requested amendments or corrections, it will issue a new communication under Rule 71(3) EPC; otherwise, it shall resume the examination proceedings (Rule 71(6) EPC).

5. Filing of a divisional application

Any divisional application relating to this European patent application must be filed directly with the European Patent Office in Munich, The Hague or Berlin and will be in the language of the proceedings for the present

application, or if the latter was not in an official language of the EPO, the divisional application may be filed in the language of the present application as filed (see Article 76(1) and Rule 36(2) EPC). Any such divisional application must be filed while the present application is still pending (Rule 36(1) EPC; Guidelines A-IV, 1.1.1).

6. Notes concerning fee payments

6.1 Making payments

For payments made via deposit account, please note that as from 1 December 2017 debit orders will only be carried out if filed in an electronically processable format (xml), using an accepted means of filing as laid down in the Arrangements for deposit accounts (ADA), published in the Supplementary publication in the Official Journal.

All relevant information related to the modes of payment of fees to the EPO can be retrieved from the EPO website at "**Making Payments**".

6.2 Information concerning fee amounts

Procedural fees are usually adjusted every two years, on even years, with effect from 1 April. Therefore, before making a payment, parties should verify the amounts actually due on the date of payment using the applicable version of the Schedule of fees and expenses, published as a Supplement to the Official Journal of the EPO, available on the EPO website (www.epo.org) at www.epo.org/schedule-of-fees. The "Schedule of fees" table allows the viewing, downloading and searching of individual fee amounts, both current and previous.

6.3 Note to users of the automatic debiting procedure

The fee for grant, including the fee for publication, and any additional claims fees due under Rule 71(4) EPC will be debited automatically on the date of filing of the translations of the claims, or on the last day of the period of this communication. However, if the designation fee(s) become(s) due as set out in Rule 71a(3) EPC and/or a renewal fee becomes due as set out in Rule 71a(4) EPC, these should be paid separately by another permitted way of payment in order not to delay the publication of the mention of the grant. The same applies in these circumstances to the payment of extension and validation fees. The same applies in these circumstances to the payment of extension and validation fees.

Note: If a waiver is expressed in response to a Rule 71(3) communication (see OJ EPO 2015, A52), the fee for grant, including the fee for publication/printing, and any additional claims fees will not be debited automatically. These fees must be paid separately by another means of payment allowed under the Rules relating to Fees.

Examining Division:

Chairman:	Beligny, Samuel
2nd Examiner:	Gettins, Marc
1st Examiner:	Cortés Suárez, José



Pfau, Andrea
For the Examining Division
Tel. No.: +49 89 2399 - 6731


Enclosures: Text intended for grant

 EPO Form 2056

- 40 -

WHAT IS CLAIMED IS

1. A compound of formula (I)



5 wherein

R¹ represents hydrogen, halogen, cyano, OH, NH₂, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)₂, CO(C₁-C₄ alkyl), CO₂(C₁-C₄ alkyl), CO₂H, CONH(C₁-C₄ alkyl), CON(C₁-C₄ alkyl)₂, SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)₂, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkyl-C₁-C₄ alkoxy or C₂-C₄ alkynyl;

10 R² represents C₃-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, R⁷ or -C₁-C₂alkyl-R⁷, each of which may be optionally substituted by one or more groups independently selected from the group consisting halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ haloalkoxy;

R³ and R⁴ independently of each other represent hydrogen, C₁-C₄ alkyl or C₃-C₆ cycloalkyl; or

15 R³ and R⁴ together with the nitrogen atom to which they are attached form a 3-6-membered saturated cyclic group;

R⁵ represents H, C₁-C₄ alkyl or C₁-C₄ haloalkyl;

R⁶ represents C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl or C₁-C₄ haloalkoxy;

20 R⁷ represents a three- to ten-membered monocyclic or fused bicyclic ring system which can be aromatic, partially saturated or fully saturated and can contain 1 to 4 hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, it being possible for the three- to ten-membered ring system itself to be optionally substituted by one or more groups independently selected from the group consisting halogen, C₁-C₄ haloalkyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;

25 and tautomers/isomers/enantiomers/salts and N-oxides of these compounds.

2. A compound of formula (I) according to claim 1 wherein

30 R¹ represents hydrogen, halogen, cyano, OH, NH₂, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)₂, CO(C₁-C₄ alkyl), CO₂(C₁-C₄ alkyl), CO₂H, CONH(C₁-C₄ alkyl), CON(C₁-C₄ alkyl)₂, SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)₂, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, or C₂-C₄ alkynyl;

- 41 -

R² represents C₃-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₆cycloalkyl, C₃-C₅cycloalkenyl, -C₁-C₂alkyl-C₃-C₆cycloalkyl, -C₁-C₂alkyl-C₃-C₆cycloalkenyl, each of which may be optionally substituted by one or more groups independently selected from the group consisting halogen, C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂ alkoxy and C₁-C₂ haloalkoxy;

5 R³ and R⁴ independently of each other represent hydrogen, C₁-C₄ alkyl or C₃-C₆ cycloalkyl; or

R³ and R⁴ together with the nitrogen atom to which they are attached form a 3-6-membered saturated cyclic group;

R⁵ represents H, C₁-C₄ alkyl or C₁-C₄ haloalkyl;

10 R⁶ represents C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl or C₁-C₄ haloalkoxy.

3. A compound of formula (I) according to either claim 1 or claim 2 wherein

R¹ represents hydrogen, halogen, cyano, OH, NH₂, methyl, ethyl, cyclopropyl, NH(C₁-C₂ alkyl), N(C₁-C₂ alkyl)₂, CO(C₁-C₂ alkyl), CO₂(C₁-C₂ alkyl), CO₂H, CONH(C₁-C₂ alkyl),
15 CON(C₁-C₂ alkyl)₂, SO₂NH(C₁-C₂ alkyl), SO₂N(C₁-C₂ alkyl)₂, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy or C₂-C₄ alkynyl;

R² represents C₃-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₆cycloalkyl, C₃-C₅cycloalkenyl, -C₁-C₂alkyl-C₃-C₆cycloalkyl, -C₁-C₂alkyl-C₃-C₆cycloalkenyl, each of which may be optionally substituted by one or more groups independently selected from the group
20 consisting halogen, C₁-C₂ alkyl, C₁-C₂ haloalkyl and C₁-C₂ haloalkoxy;

R³ and R⁴ independently of each other represent hydrogen, C₁-C₃ alkyl or C₃-C₅ cycloalkyl; or

R³ and R⁴ together with the nitrogen atom to which they are attached form a 5-membered saturated cyclic group;

25 R⁵ represents H or C₁-C₄ alkyl;

R⁶ represents C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl or C₁-C₄ haloalkoxy.

4. A compound of formula (I) according to any preceding claim wherein

R¹ represents hydrogen, halogen, cyano, OH, NH₂, methyl, ethyl, cyclopropyl, NHMe, NMe₂, COMe, CO₂Me, CO₂H, CONHMe, CONMe₂, SO₂NHMe, SO₂NMe₂, CHF₂, CF₃, OMe, OCHF₂ or acetylenyl;
30

R² represents C₃-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₆cycloalkyl, C₃-C₅cycloalkenyl, -C₁-C₂alkyl-C₃-C₆cycloalkyl, -C₁-C₂alkyl-C₃-C₆cycloalkenyl which may be optionally substituted by one or more groups independently selected from the group
35 consisting fluoro, C₁-C₂ alkyl, C₁-C₂ fluoroalkyl and C₁-C₂ fluoroalkoxy;

- 42 -

R³ and R⁴ independently of each other represent hydrogen, methyl, ethyl, isopropyl or cyclopropyl; or

R³ and R⁴ together with the nitrogen atom to which they are attached form a 5-membered saturated cyclic group;

5 R⁵ represents H or methyl;

R⁶ represents C₁-C₄ alkyl or C₁-C₄ alkoxy.

5. A compound of formula (I) according to any preceding claim wherein

10 R₁ represents hydrogen, halogen, cyano, methyl, ethyl, cyclopropyl, CHF₂, CF₃, OMe, or OCHF₂;

R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, 2-methylpentyl, 3-methylpentyl, 2,3-dimethylbutyl, 2,2-dimethylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl -CH₂-cyclopropyl, -CH₂-cyclobutyl, -CH₂-cyclopentyl, and -CH₂-cyclopentenyl, each of which may be optionally substituted by one or
15 more groups independently selected from the group consisting fluoro, methyl and difluoromethoxy;

R³ is hydrogen or methyl;

R⁴ is methyl or ethyl;

R⁵ represents H or methyl;

20 R⁶ represents methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy or ethoxy.

6. A compound of formula (I) according any preceding claim wherein

R¹ represents hydrogen, Cl, Br, methyl, CHF₂ or cyano;

25 R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, each of which may be optionally substituted by one or more groups independently selected from the group consisting fluoro and difluoromethoxy;

R³ represents hydrogen or methyl;

R⁴ is ethyl;

30 R⁵ is hydrogen or methyl;

R⁶ represents methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy or ethoxy.

7. A compound of formula (I) according any preceding claim wherein

35 R¹ represents hydrogen, Cl, Br, methyl, CHF₂ or cyano;

- 43 -

R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, each of which may be optionally substituted by one or more groups independently selected from the group consisting fluoro and difluoromethoxy;

R³ represents hydrogen or methyl;

5 R⁴ is ethyl;

R⁵ is hydrogen or methyl;

R⁶ represents methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, cyclobutyl or cyclopentyl.

8. A compound of formula (I) according any preceding claim wherein

10 R¹ represents hydrogen, Cl, Br, methyl, CHF₂ or cyano;

R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, each of which may be optionally substituted by one or more groups independently selected from the group consisting fluoro and difluoromethoxy;

R³ represents hydrogen or methyl;

15 R⁴ is ethyl;

R⁵ is hydrogen or methyl;

R⁶ represents methyl, ethyl, n-propyl or iso-propyl.

9. A compound of formula (I) according any preceding claim wherein

20 R¹ represents hydrogen, Cl, Br, methyl, CHF₂ or cyano;

R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, each of which may be optionally substituted by one or more groups independently selected from the group consisting fluoro and difluoromethoxy;

R³ represents hydrogen or methyl;

25 R⁴ is ethyl;

R⁵ is hydrogen or methyl;

R⁶ is methyl.

10. A compound of formula (I) according any preceding claim wherein

30 R¹ represents hydrogen, Cl, Br, methyl, CHF₂ or cyano;

R₂ is n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or cyclopropyl;

R³ represents hydrogen or methyl;

R⁴ is ethyl;

R⁵ is hydrogen;

35 R⁶ is methyl.

- 44 -

11. A compound of formula (I) according to claim 1 wherein the compound is:

N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine (compound 67.002); or

5 N'-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine (compound 67.003); or

N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine (compound 67.013); or

N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine (compound 67.015); or

10 N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine (compound 67.018).

12. A composition comprising a fungicidally effective amount of a compound of formula (I) as defined in any one of claims 1 to 10, optionally comprising at least one additional active
15 ingredient.

13. A method of controlling or preventing phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a fungicidally effective amount of a compound of
20 formula (I) as defined in any one of claims 1 to 10.